Millennium Post

SC agrees to hear PIL seeking Ranbaxy’s licence cancelation

The Supreme Court on Monday agreed to hear a Public Interest Litigation (PIL) seeking cancellation of the licence and initiation of probe against Ranbaxy Laboratories Ltd for allegedly manufacturing and selling adulterated medicines. The court will hear the case on 24th of this month.

An apex court vacation bench of Justice A K Patnaik and Justice Ranjan Gogoi agreed to hear the PIL after petitioner advocate M L Sharma pleaded for an urgent hearing in the case.

Earlier another vacation bench had asked the petitioner Sharma to substantiate unfounded allegations against the pharma company and then Sharma filed an additional affidavit in the case.

The petition by Sharma has sought sealing of all manufacturing units of the pharma company, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh. It has also sought action against Central Drug Standards Control Organisation (CDSCO) – Indian drug regulator – for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the USFDA probe against the company.

The petition has alleged that the company has been fined USD 500 million by the US Food and Drug Administration (USFDA) for making and selling adulterated drugs.

It has alleged that despite Ranbaxy pleading guilty to supplying adulterated drugs in the US and it being fined such a huge amount, the central government has not taken any action to prohibit or ban the drugs made by the company.


Our contributor helps bringing the latest updates to you

Share it